4 results
1. To assess the effect of odanacatib 50 mg once weekly versus placebo on lumbar spine BMD over 24 months.2. To assess the safety and tolerability of odanacatib 50 mg once weekly compared to placebo.
Objective: To demonstrate the efficacy of a novel matrix therapy based technology that creates improved wound healing in a clinical donor site model.
Does antagonism of the adenosine receptor by caffeine lead to an increased LPS-induced inflammatory reaction and an increase in (subclinical) tissuedamage?Does the C34T-polymorphism of the enzyme AMP-deaminase lead to a decreased inflammatory…
The aim of this study is to prove feasibility of HAIP chemotherapy (floxuridine) in combination with standard systemic chemotherapy consisting of FOLFOX or FOLFIRI.